clinical trial · NCT07060547
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
HepQuant, LLC·—·recruiting·n = 40
Alcoholic HepatitisAlcohol-related Liver DiseaseHepQuant DuO Test
brief summary
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.
started
Jun 10, 2025
primary completion
Dec 1, 2031
completion
Mar 1, 2032
last updated
Jul 11, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol